The Raf/MEK1/2 [mitogen-activated protein kinase/ERK (extracellular-signal-regulated kinase) kinase 1/2]/ERK1/2 signalling pathway is frequently activated in human tumours due to mutations in BRAF or KRAS. B-Raf and MEK1/2 inhibitors are currently undergoing clinical evaluation, but their ultimate success is likely to be limited by acquired drug resistance. We have used colorectal cancer cell lines harbouring mutations in B-Raf or K-Ras to model acquired resistance to the MEK1/2 inhibitor selumetinib (AZD6244). Selumetinib-resistant cells were refractory to other MEK1/2 inhibitors in cell proliferation assays and exhibited a marked increase in MEK1/2 and ERK1/2 activity and cyclin D1 abundance when assessed in the absence of inhibitor. This was driven by a common mechanism in which resistant cells exhibited an intrachromosomal amplification of their respective driving oncogene, B-Raf V600E or K-Ras G13D . Despite the increased signal flux from Raf to MEK1/2, resistant cells maintained in drug actually exhibited the same level of ERK1/2 activity as parental cells, indicating that the pathway is remodelled by feedback controls to reinstate the normal level of ERK1/2 signalling that is required and sufficient to maintain proliferation in these cells. These results provide important new insights into how tumour cells adapt to new therapeutics and highlight the importance of homoeostatic control mechanisms in the Raf/MEK1/2/ERK1/2 signalling cascade.
Introduction
The ERK1/2 (extracellular-signal-regulated kinase 1/2) signalling cascade [also known as the MAPK (mitogenactivated protein kinase) pathway] consists of a threetier hierarchical cascade of protein kinases in which a member of the Raf kinase family (A-Raf, B-Raf or CRaf) phosphorylates and activates the dual-specificity protein kinases MEK (MAPK/ERK kinase) 1 and MEK2, which in turn phosphorylate and activate ERK1 and ERK2 [1] . Activation of the pathway is co-ordinated by the binding of the active GTP-bound form of the Ras GTPases (H-Ras, NRas and K-Ras) to Raf [2] . Active ERK1/2 can phosphorylate a variety of substrates [1] to promote cell proliferation, cell motility and cell survival. ERK1/2 substrates include nuclear targets such as the ETS and AP-1 (activator protein 1) transcription factors and non-nuclear targets such as apoptotic regulators [3] . The ERK1/2 pathway plays a critical role in promoting cell proliferation [4] and is especially important in driving the expression of the D-type cyclins, such as cyclin D1, to promote progression through the G 1 -phase of the cell cycle [5] .
Increased or inappropriate proliferation and survival are among the hallmarks of the cancer cell [6] and the ERK1/2 cascade is frequently deregulated in human cancer as a result of activating mutations in the BRAF or RAS genes [2, 7] . Tumour cells typically adapt to become 'addicted' to these oncogenes and their downstream signalling pathways to maintain their tumorigenic properties [8] . As a result, the ERK1/2 pathway has been the focus of a search for new targeted anticancer therapeutics; indeed, inhibitors of B-Raf (e.g. PLX-4032) and MEK1/2 (e.g. selumetinib/AZD6244 and GSK1120212) are currently undergoing clinical evaluation [7] . PLX-4032 specifically inhibits the mutant BRaf V600E oncoprotein and the results of Phase III clinical trials in advanced B-Raf V600E melanoma show significant benefits of PLX-4032 over the standard of care comparator [9] . However, this and other B-Raf inhibitors may actually increase ERK1/2 activation and tumorigenesis in tumours that have K-Ras, N-Ras or receptor tyrosine mutations due to Ras-dependent drug-induced transactivation of C-Raf bound to B-Raf or C-Raf homodimers [10, 11] . In contrast, MEK1/2 inhibitors such as selumetinib can inhibit ERK1/2 activation, regardless of whether it is driven by mutations in B-Raf, KRas or receptor tyrosine kinases. Consequently, inhibition of MEK1/2 remains an attractive treatment strategy for a variety of tumours 'addicted' to ERK1/2 signalling, although combination therapy is likely to be required to fully exploit their therapeutic effect.
Experience has shown that tumour cells can develop acquired resistance to oncogene-targeted agents, resulting in (A) In colorectal cancer cells harbouring the B-Raf V600E oncoprotein (represented by the star), the level of active p-ERK1/2 is maintained by activation of just a small fraction of MEK1/2. The selective MEK1/2 inhibitor selumetinib (white cross) inhibits this to block ERK1/2 activation and promote cell-cycle arrest. Two mechanisms of acquired resistance to MEK12 inhibitors have been reported to date; both share the common feature of maintaining p-ERK1/2 levels in the presence of drug. (B) The emergence of a point mutation in MEK1 (MEK1 P124L , represented by the star) was found in a B-Raf V600E -positive melanoma patient receiving selumetinib who exhibited disease progression [28] . This mutant confers selumetinib-independent ERK1/2 activation when expressed in heterologous cell systems, thereby maintaining ERK1/2 activation in the presence of selumetinib. (C) Pre-clinical models in B-Raf V600E -positive human colorectal cancer cell lines have shown that acquired resistance to selumetinib is driven by the selective amplification of the mutant B-Raf V600E allele [12, 15] . This greatly increases the fraction of active MEK1/2, thereby necessitating higher doses of drug. The level of p-ERK1/2 is remodelled to the parental level despite the large increase in p-MEK1/2. This may be achieved by the action of ERK1/2 phosphatases such as the DUSPs. Note: the increase in number of MEK molecules in (C) is simply artistic licence to represent the increase in the number of active MEK molecules resulting from B-Raf V600E amplification. There is no evidence to suggest that MEK itself is amplified.
disease progression. It is therefore important to identify the underlying mechanisms so that we can develop strategies to delay the onset of resistance or overcome it once it has emerged. Significantly, numerous reports have shown that pre-clinical studies in human tumour cell lines can be remarkably useful in identifying mechanisms of resistance that emerge in the clinic. To this end, we used human colorectal cancer cells with mutations in either B-Raf V600E (COLO205 or HT29; Figure 1 ) or K-Ras G13D (HCT116 and LoVo; Figure 2 ) to model acquired resistance to the MEK1/2 inhibitor selumetinib [12] . These cells were chosen because they exhibited primary sensitivity to selumetinib, indicating that they were 'addicted' to ERK1/2 signalling for their normal proliferation [13] . Cells were rendered resistant to selumetinib by either a dose-escalation protocol or a continuous C max protocol, in which cells were selected in 1 or 2 μM. Notably, both protocols gave the same results, giving rise to cell lines that were refractory to the anti-proliferative effects of selumetinib. Resistant cells were cross-resistant to other specific MEK1/2 inhibitors such as PD184352 (CI-1040), but remained sensitive to classical chemotherapeutic agents that are known to be substrates for MDR (multidrugresistance) drug transporters, suggesting that resistance was unlikely to be mediated by MDR proteins, but rather was related to ERK1/2 pathway inhibition.
Amplification of B-Raf V600E drives acquired resistance to MEK1/2 inhibitors in cancer cells with B-Raf

V600E
Parental COLO205 cells (B-Raf V600E ) were very sensitive to MEK1/2 inhibition by selumetinib or PD184352 [13, 14] and exhibited loss of active phosphorylated ERK1/2 (p-ERK1/2), loss of cyclin D1 expression, increased expression of the CDK (cyclin-dependent kinase) inhibitor p27 KIP1 and a G 1 cellcycle arrest. Selumetinib-resistant COLO205 cells (C6244-R cells) were up to 50-fold more resistant to selumetinib and exhibited an increase in basal cyclin D1 expression and lower basal p27 KIP1 expression. C6244-R cells also exhibited a striking increase in both active p-MEK1/2 and active p-ERK1/2 in the absence of drug ( Figure 1 ). Re-addition of selumetinib to C6244-R cells confirmed that the increase in active ERK1/2 and cyclin D1 expression was still subject to regulation by selumetinib, but 20-fold higher levels of drug were required to achieve the same effect as in parental cells. This argued that resistance was unlikely to be due to the emergence of mutations in MEK1 or MEK2 that might abrogate selumetinib binding; indeed, we failed to detect mutations in MEK1 and MEK2.
The increase in p-MEK1/2 and p-ERK1/2 in C6244-R cells suggested activation of the pathway upstream of Pre-clinical models in K-Ras G13D -positive human colorectal cancer cell lines have shown that acquired resistance to selumetinib (represented by the stars) is driven by the selective amplification of the mutant K-Ras G13D allele (white cross) [12] (right-hand panel). This greatly increases the fraction of active MEK1/2, thereby necessitating higher doses of drug to inhibit ERK1/2 activation. As with cells with amplified B-Raf V600E , the level of p-ERK1/2 is remodelled to the parental level despite the large increase in p-MEK1/2 so that the ERK1/2 output is maintained in the presence of drug. Amplification of K-Ras G13D also leads to hyperactivation of other K-Ras effector pathways such as the PI3K/PDK1/PKB pathway and conceivably Ral and PLCε (represented by ?), causing qualitative differences in signalling output compared with parental cells. This may confound efforts to overcome resistance by drug combinations. Note: the increase in number of C-Raf, MEK, PI3K, PDK1 and PKB molecules in resistant cells is simply artistic licence to represent the increase in the number of active molecules resulting from K-Ras G13D amplification. There is no evidence to suggest that these components are also amplified. Figure 1) ; indeed, C6244-R cells exhibited a large increase in B-Raf expression, whereas C-Raf expression was normal. Genomic Q-PCR (quantitative PCR) demonstrated that BRAF copy number was increased by a factor of 4-5 in C6244-R cells, whereas FISH (fluorescence in situ hybridization) coupled with chromosome painting revealed an intrachromosomal amplification of the BRAF locus on chromosome 7. Sequencing of BRAF exon 15 demonstrated that the increased abundance of B-Raf was due to the selective amplification of mutant B-Raf V600E ( Figure 1C ). Finally, RNAi (RNA interference)-mediated knockdown of B-Raf inhibited the increase in p-ERK1/2 and resensitized C6244-R cells to selumetinib, indicating that amplified BRaf V600E is required to maintain selumetinib resistance in C6244-R cells. We also generated selumetinib-resistant HT29 cells and found that they exhibited a very similar profile of increased B-Raf, p-MEK1/2 and p-ERK1/2. In parallel with these studies, Corcoran et al. [15] also generated selumetinibresistant versions of COLO201 and COLO206F, two further colorectal cancer cells lines with B-Raf V600E mutations. In both cases, selumetinib resistance was associated with amplification of B-Raf V600E , and RNAi-mediated knockdown of B-Raf V600E resensitized the resistant COLO201 cells to selumetinib. Finally, overexpression of B-Raf V600E in COLO201 or WM164 melanoma cells was sufficient to confer resistance to selumetinib [15] .
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Ras proteins can activate multiple effector pathways in addition to Raf/MEK1/2/ERK1/2 [2] and at least one of these, the PI3K (phosphoinositide 3-kinase)/PDK1 (phosphoinositide-dependent kinase 1)/PKB (protein kinase B) pathway, can confer intrinsic resistance to MEK1/2 inhibitors [13, 16] . For these reasons, it was important to model selumetinib resistance in cells with K-Ras mutations as well as those with B-Raf V600E . In common with COLO205 cells, HCT116 cells (K-Ras G13D ) were sensitive to MEK1/2 inhibition by selumetinib [13] and underwent a G 1 cell-cycle arrest with reduced expression of cyclin D1 and increased p27 KIP1 . Selumetinib-resistant HCT116 cells (H6244-R cells) were >100-fold resistant to selumetinib and exhibited an increase in basal cyclin D1 expression that was completely refractory even to very high doses of selumetinib. Like C6244-R cells, H6244-R cells exhibited increased p-MEK1/2 and p-ERK1/2 in the absence of drug (Figure 2 ), but again p-ERK1/2 levels were still inhibited by very high levels of selumetinib, consistent with the lack of any mutations in MEK1 and MEK2.
In the case of H6244-R cells, the increase in p-ERK1/2 and p-MEK1/2 was not due to changes in abundance of B-Raf or C-Raf, but rather to a substantial increase in KRas (Figure 2 ). Whereas increased expression of K-Ras was reported previously in the murine C26 carcinoma cell line rendered resistant to PD184352 (CI-1040) [17] , this study did not determine whether K-Ras expression was driving resistance or determine the mechanism for the increase in K-Ras abundance [17] . Our analysis revealed that the increase in K-Ras expression was due to an intrachromosomal amplification of the KRAS locus on chromosome 12 and sequencing confirmed that it was the mutant K-Ras G13D allele that was selected for amplification ( Figure 2 ). In addition, RNAi-mediated knockdown of K-Ras inhibited the increase in p-ERK1/2 and resensitized H6244-R cells to selumetinib, indicating that amplified K-Ras G13D drives acquired resistance to selumetinib in H6244-R cells. Finally, selumetinibresistant LoVo cells (also K-Ras G13D ) exhibited a very similar profile, with increased expression of K-Ras and increased p-MEK1/2 and p-ERK1/2. Together, these results demonstrate that amplification of mutant K-Ras G13D is selected for and drives acquired resistance to selumetinib in tumour cell lines.
How do selumetinib-resistant cells adapt to accommodate amplification of the driving oncoprotein?
These results [12, 15] demonstrate that acquired resistance to MEK1/2 inhibitors, including those that are currently undergoing clinical evaluation, can arise through a common mechanism involving amplification of the driving oncoprotein (i.e. B-Raf V600E or K-Ras G13D ) and increased signal flux down the MEK1/2/ERK1/2 pathway. This raises several interesting questions, including how do such amplification events arise, how do they drive hyperactivation of the ERK1/2 pathway, and how does the pathway adapt to such changes?
In both COLO205 (B-Raf V600E ) and HCT116 (KRas G13D ) cells, the driving oncogenes were amplified by an apparently similar mechanism involving an intrachromosomal amplification. Human cancer cells can use several mechanisms of amplification and there are probably others yet to be discovered. Two well-established examples are the breakage-fusion-bridge cycle (repeated fusion and breakage of chromosomes after fusion of sister chromatids at a double-strand break) or the formation of double-minute chromosomes (episomal amplification of acentric DNA fragments) followed by their reintegration [18] . The details are beyond the scope of the present article, but several observations suggest that these amplification events may preexist at low incidence in tumours and serve as founder events. First, the COLO205 cell line has a pre-existing trisomy of chromosome 7, where B-Raf is found [12] . Secondly, in the COLO201 and COLO206F cell lines, occasional cells showed a pre-existing amplification of B-Raf [15] . Thirdly, at least one naïve primary human colorectal cancer specimen known to harbour B-Raf V600E exhibited a substantial preexisting BRAF gene amplification [15] . These results suggest that selumetinib-resistant cells arise by classical Darwinian selection of clones with pre-existing amplification of B-Raf V600E or K-Ras G13D . In the parental tumour cells (B-Raf V600E or K-Ras G13D ), the level of p-ERK1/2 required to sustain proliferation was maintained by phosphorylation and activation of a very small fraction of MEK1/2, underlining the degree of signal amplification that can take place at this step in the pathway. In contrast, selumetinib-resistant cells exhibited much higher levels of p-MEK1/2, reflecting increased signal flux from the amplified B-Raf V600E or K-Ras G13D . Since allosteric inhibitors such as selumetinib and PD184352 do not prevent phosphorylation of MEK1/2 by Raf [19] , but rather stabilize an inactive conformation of the enzyme [20] , these results suggest that the larger pool of activated MEK1/2 driven by amplified B-Raf V600E or K-Ras G13D in selumetinib-resistant cells necessitates more drug to inhibit the pathway and so disrupt downstream signalling ( Figures 1C and 2 ). The increase in signal flux to p-MEK1/2 driven by B-Raf V600E or K-Ras G13D amplification may be exacerbated by the disruption of a well-known negativefeedback loop that operates in this pathway, whereby active ERK1/2 can phosphorylate Raf proteins and so inhibit MEK phosphorylation [21] ; this feedback loop is impaired in cells with B-Raf V600E [22] and was also reduced in selumetinibresistant HCT116 cells [12] In the absence of selumetinib, drug-resistant cells exhibited a striking increase in p-MEK1/2, p-ERK1/2 and increased expression of known ERK1/2 target genes such as members of the AP-1 transcription factors [12] . Despite this, when the selumetinib-resistant cells were maintained in their normal selection medium (i.e. in selumetinib), they actually exhibited a normal parental level of p-ERK1/2 despite the increase in p-MEK1/2 arising from amplified B-Raf V600E or K-Ras G13D [12] ( Figures 1C and 2 ) At present, we do not know why or how the level of ERK1/2 activity is remodelled like this, but it is interesting to speculate. First, whereas ERK1/2 signalling clearly drives cell proliferation and is required for proliferation of the parental tumour cells, excessive ERK1/2 activation can promote cell-cycle arrest [23] , senescence [24] and autophagic cell death [25] . We suggest that ERK1/2 activation has to operate within strict limits to maintain proliferation instead of quiescence (too little ERK1/2 activity) or senescence or autophagy (too much activity), and that AZD6244-resistant tumour cells must remodel ERK1/2 activity to ensure these limits are not crossed. Quite how this is achieved is unclear, other than by the selective pressure exerted by the need to proliferate in the presence of drug, but since p-MEK1/2 levels remain high even when p-ERK1/2 levels are dampened down, this might suggest a role for MAPK phophatases such as the DUSPs (dual-specificity phosphatases) in resetting p-ERK1/2 levels ( Figure 1C) ; certainly the expression of some DUSPs is elevated in the selumetinib-resistant cells [12] . Future experiments will seek to test these ideas.
Therapeutic strategies to overcome or delay the onset of acquired resistance to selumetinib
The identification of drivers of acquired resistance may allow rational intervention with small-molecule inhibitors to overcome resistance. In the case of C6244-R cells with amplified B-Raf V600E , this proved to be true; combining selumetinib treatment with the pan-Raf inhibitor AZ628 was able to overcome acquired resistance to selumetinib in COLO205 [12] , COLO201 and COLO206F cells [15] . These results suggest that the combination of MEK1/2 and B-Raf inhibitors may be more effective as a primary treatment and may prevent or delay the onset of acquired resistance in tumours with B-Raf V600E ; indeed, a clinical trial of BRaf + MEK inhibitors is underway (http://clinicaltrials.gov identifiers NCT01072175 and NCT01231594).
In contrast, acquired resistance to selumetinib in cells with amplified K-Ras G13D is far more complex. In addition to enhanced signalling to p-MEK1/2 to maintain p-ERK1/2 levels, H6244-R cells exhibited a substantial increase in activation of the PI3K/PDK1/PKB pathway compared with parental cells, and the same was seen in selumetinib-resistant LoVo cells [12] (Figure 2) . Some tumour cells exhibit intrinsic resistance to selumetinib due to hyperactivation of this pathway and combination of selumetinib with PI3K or PKB inhibitors is effective at inhibiting their proliferation [13, 16] ; indeed, the combination of selumetinib and the PKB inhibitor MK-2206 is currently undergoing clinical evaluation (http://clinicaltrials.gov identifier NCT01021748). However, combination with a mixed PI3K/mTOR (mammalian target of rapamycin) inhibitor was unable to overcome selumetinib resistance in H6244-R cells even when both drugs were effective at inhibiting their target pathways [12] . Thus, whereas combination of MEK1/2 inhibitors with PI3K or PKB inhibitors may be effective as a primary treatment, it is not clear whether it will be effective at overcoming acquired resistance to MEK1/2 pathway inhibitors in tumour cells with Ras mutations. These results suggest that KRas effector pathways other than Raf/MEK1/2/ERK1/2 or PI3K/PDK1/PKB may contribute to K-Ras G13D -driven selumetinib resistance in these cells (Figure 2 ). This includes pathways leading to the activation of PLCε (phospholipase Cε), to mobilize Ca 2 + and activate protein kinase C, or the Ral GTPases [2] ; their role in MEK1/2 inhibitor resistance is currently unknown. Finally, it is also possible that amplification of K-Ras G13D may drive resistance by more stable epigenetic changes, an emerging area that is poorly understood [26] .
Resistance to MEK1/2 inhibitors: multiple mechanisms but a common theme
Acquired resistance to tyrosine kinase inhibitors such as the EGFR (epidermal growth factor receptor) inhibitor gefitinib or the Bcr-Abl inhibitor imatinib can arise by multiple mechanisms including the emergence of secondary mutations in the kinase domain that abrogate drug binding [27] . Interestingly, saturation mutagenesis studies have identified point mutations in MEK1 that confer resistance to PD184352 or selumetinib [19, 28] ; some of these were clustered in the hydrophobic drug-binding pocket, so it seems plausible that they may interfere with drug binding. In addition to these manufactured MEK1 mutants, a MEK1 P124L mutation was also identified in a resistant metastatic lesion from a melanoma patient treated with selumetinib [28] . This mutation lies outside the hydrophobic pocket and so is unlikely to abrogate drug binding; however, its proximity to the N-terminal regulatory domain of MEK1 suggests that it may drive resistance by increasing MEK1 kinase activity. Certainly, it does allow ERK1/2 activation to persist even in the presence of maximal doses of selumetinib [28] . Thus acquired resistance to MEK1/2 inhibitors can arise by the emergence of drug-resistant mutations in the primary drug target (MEK1/2) [28] (Figure 1B) or by amplification of upstream signalling to increase the fraction of active MEK1/2 [12, 15] ( Figures 1C and 2) ; however, both mechanisms share a common theme in which they effectively bypass the inhibited enzyme to re-establish ERK1/2 pathway output in the presence of drug, underlining the extent to which these cells are 'addicted' to the ERK1/2 pathway. Such multiple mechanisms of resistance are reminiscent of that seen with tyrosine kinase inhibitors [27] , highlighting the remarkable adaptability of tumour cells to novel targeted therapeutics.
Summary
In most instances, selumetinib and related MEK1/2 inhibitors cause tumour cells to arrest in the G 1 -phase of the cell cycle, rather than undergoing cell death. It seems likely that such cytostatic responses may provide the tumour cell with the opportunity to adapt to the drug and develop resistance. Identifying mechanisms of acquired resistance should help to identify drug combinations that overcome it or delay its onset. In addition, it will be important to identify drugs that, when combined with selumetinib, switch the primary phenotypic response of MEK1/2 inhibition from cytostatic to cytotoxic. This should provide greater primary efficacy and reduce and/or delay the onset of acquired resistance.
